Wird geladen...
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
BACKGROUND: We determined whether the market exclusivity incentive of the European Orphan Drug Regulation results in a market monopoly or that absence of another Orphan Medicinal Product (OMP) for the same rare disorder, a so-called follow-on OMP, is a matter of time or market size. In the interest...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3185263/ https://ncbi.nlm.nih.gov/pubmed/21892964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-6-59 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|